Calcitonin gene-related peptide - Akela Pharma

Drug Profile

Calcitonin gene-related peptide - Akela Pharma

Alternative Names: Akela CGRP; CGRP - Akela Pharma; LAB CGRP

Latest Information Update: 18 Mar 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Sherbrooke
  • Developer Akela Pharma
  • Class Antiarrhythmics; Antiasthmatics; Neuropeptides; Vasodilators
  • Mechanism of Action Calcitonin gene-related peptide agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 14 Mar 2013 Discontinued - Phase-II for Asthma in European Union (Inhalation)
  • 11 Sep 2009 CGRP is available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top